In short
MAQUET Cardiopulmonary, a business unit of MAQUET Cardiovascular and a leader in extracorporeal life support (ECLS) systems, has announced that it has signed an agreement with Avalon Laboratories to acquire its Avalon Elite® Bi-Caval Dual Lumen Catheter and complimentary vascular access kits for use during ECLS. The terms of the deal have not been released.
Background
Avalon’s patented Elite® Bi-Caval Dual Lumen Catheter is FDA cleared for simultaneous venous drainage and reinfusion of blood via the internal jugular vein during extracorporeal life support procedures. The catheter is designed to increase the efficiency of blood gas exchange by draining blood from both the upper and lower body while simultaneously re-infusing it directly into the heart. The catheter is also designed to minimise recirculation and maximize blood flow while providing a less invasive solution for the patient.
The Avalon Elite® Bi-Caval Dual Lumen Catheter has received 510(k) clearance from the U.S. Food and Drug Administration and the CE Mark from the European Medicines Agency.
The product complements Maquet’s cannula product line which also includes the state-of-the-art HLS single lumen cannula line and conventional double lumen pediatric cannulae. The Avalon Elite® product range will be available via the MAQUET global sales and distribution channels as well as through existing Avalon distributors and will be sold under the Trademark Avalon Elite®.
Company comments
for Maquet
“It was our Cardiopulmonary business unit which started a paradigm shift in moving extracorporeal life support into routine medical practice, most notably through the introduction of new products such as CARDIOHELP,” said Christian Keller, President and Chief Executive Officer of MAQUET Cardiovascular. “Through the acquisition of the most advanced double lumen cannula we finally provide our customers a complete range of best in class products from tip to tip.”
“With the addition of the Avalon Elite® catheter line, we now offer the customers and patients we serve with a full range of minimally invasive venous or arterial cannulation techniques for ECLS,” said Dr. Wolfgang Rencken. “The Avalon Elite® Bi-Caval Dual Lumen Catheter is a state of the art ECLS technology that sets the standard for new MAQUET catheter offerings in the future and will play an integral role in new cardiopulmonary offerings from MAQUET.”
for Avalon Laboratories
“MAQUET’s growing leadership in the cardiopulmonary space makes our Bi-Caval Dual Lumen Catheter the ideal acquisition to further expand the number of patients globally who can benefit from this device,” said Michael Janish, Chief Executive Officer of Avalon Laboratories.
Source: Maquet Cardiovascular, PR Newswire
published: May 30, 2012 in: Cardio, Mergers and Acquisitions